Compare BridgeBio Pharma Inc (BBIO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Ross Stores, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Ross Stores, Inc. trades at $221.99 (market cap $70.87B). The key difference: Ross Stores, Inc. is far larger — about 4.3× BridgeBio Pharma Inc's market cap, and Ross Stores, Inc. pays a 0.81% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ROST | |
|---|---|---|
Market Cap | $16.46B | $70.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $240.13 |
52-Week Low | $44.81 | $127.59 |
Enterprise Value | $18.02B | $71.46B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Ross Stores (ROST) trades at $219.46, down 1.53% on the day, with a bullish technical outlook supported by moving averages and consistent earnings beats. The company demonstrates strong profitability with a 9.74% net margin and 38.98% ROE, while revenue grew to $21.13B in 2025. Recent news highlights robust Q1 2026 performance with 21% sales growth and expanding margins.
The stock offers upside to the $259 consensus price target, driven by operational efficiency and store expansion. Risks include consumer spending sensitivity and competitive pressures. Analyst sentiment is strongly positive with 64% buy ratings, though valuation multiples like the 30.65 P/E warrant monitoring amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
